MedChunk
Medically reviewed

Macular Degeneration Treatment Options: What Works

Explore effective macular degeneration treatments, including anti-VEGF injections, AREDS2 vitamins, geographic atrophy therapies, laser treatment, and vision rehabilitation.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateJul 6, 2025 12 min read

Macular degeneration cannot currently be cured, but several treatments can slow vision loss and help protect remaining eyesight. Anti-VEGF eye injections are the main treatment for wet macular degeneration, while AREDS2 supplements can help certain people with dry macular degeneration. Newer injections can also slow an advanced form of dry macular degeneration called geographic atrophy. The best option depends on the type and stage of the disease.

Which Macular Degeneration Treatments Actually Work?

Age-related macular degeneration (AMD) affects the macula, the part of the retina responsible for sharp central vision. It can make reading, recognizing faces, and seeing fine details more difficult.

Treatment works differently depending on whether AMD is dry or wet. According to the National Eye Institute, treatment choices depend on the disease's stage and type. Some treatments help prevent progression, while others control abnormal blood vessels or support daily activities when vision has already changed.

Dry versus wet macular degeneration treatment

Dry AMD is the more common form and usually progresses gradually. Early dry AMD does not require medication, but regular monitoring is important. At the intermediate stage, specific nutritional supplements may reduce the risk of progression.

Wet AMD develops when abnormal blood vessels grow beneath the retina. These vessels can leak fluid or blood and damage central vision. Because wet AMD may progress quickly, prompt treatment is particularly important.

Advanced dry AMD may involve geographic atrophy, in which retinal cells gradually deteriorate. Newer medicines can slow the growth of damaged areas, although they cannot restore cells that have already been lost.

Anti-VEGF Injections: The Main Treatment for Wet AMD

Anti-vascular endothelial growth factor (anti-VEGF) medications are considered the first-line treatment for wet macular degeneration. These medicines block signals that encourage abnormal blood vessels to grow and leak.

By reducing fluid leakage and bleeding, anti-VEGF treatment can stabilize vision and sometimes improve eyesight. Results depend on factors such as existing retinal damage, the timing of treatment, and how the eye responds.

The National Eye Institute identifies anti-VEGF injections as the most commonly used treatment for wet AMD. Most patients require repeated injections because the medicines do not provide permanent control after one dose.

Which anti-VEGF medicines are used?

Several medicines are used to treat wet AMD, including:

  • Aflibercept (Eylea): Helps control abnormal blood vessel growth and fluid leakage.
  • Ranibizumab (Lucentis): Targets VEGF to reduce leaking blood vessels.
  • Bevacizumab (Avastin): Sometimes used off-label for wet AMD.
  • Faricimab (Vabysmo): Targets VEGF-A and angiopoietin-2, two pathways involved in abnormal blood vessel activity.
  • Brolucizumab (Beovu): Another VEGF-blocking option, although safety considerations affect its use.

These medicines differ in their dosing schedules, risks, and suitability. A retina specialist selects treatment based on retinal examination findings, response to previous medication, and individual circumstances.

What happens during an eye injection?

Although receiving an injection in the eye may sound uncomfortable, the procedure is usually brief and performed in an outpatient setting.

The ophthalmologist first uses numbing medication and cleans the eye to reduce infection risk. A very small needle then delivers the medicine into the vitreous, the gel-like substance inside the eye.

Some people notice temporary irritation or a small red area afterward. More serious complications, including infection, inflammation, increased eye pressure, or retinal detachment, are uncommon but require medical attention.

How often are anti-VEGF injections needed?

Many treatment plans begin with injections approximately every four weeks. The ophthalmologist may later adjust the interval based on retinal scans and the eye's response.

Some people need continued frequent injections, while others can have longer intervals between appointments. Skipping recommended treatment can allow abnormal blood vessel activity to return.

Can AREDS2 Vitamins Slow Dry Macular Degeneration?

AREDS2 supplements can help reduce the risk of progression to advanced AMD in certain patients, particularly those with intermediate AMD in one or both eyes or advanced AMD in only one eye.

AREDS2 stands for the second Age-Related Eye Disease Study. The formula contains specific amounts of vitamins, minerals, and carotenoids that were studied for their effects on AMD progression.

According to the National Eye Institute, AREDS2 supplements are not effective at preventing early AMD from becoming intermediate AMD. They also do not restore vision that has already been lost.

What is in the AREDS2 formula?

The studied AREDS2 formulation contains:

  • Vitamin C: 500 mg
  • Vitamin E: 400 international units
  • Lutein: 10 mg
  • Zeaxanthin: 2 mg
  • Zinc: 80 mg
  • Copper: 2 mg

These amounts are considerably higher than those found in many standard multivitamins. Taking ordinary eye-health supplements is not necessarily equivalent to taking the tested AREDS2 formula.

The newer AREDS2 formula does not contain beta-carotene. This distinction matters because beta-carotene supplements have been linked to an increased lung cancer risk in people who smoke or previously smoked.

Patients should discuss AREDS2 with their ophthalmologist before starting it, especially when taking other medicines or supplements. These products are not recommended for everyone with AMD.

New Injections for Advanced Dry AMD: Geographic Atrophy

Geographic atrophy is an advanced form of dry AMD that causes progressive loss of retinal tissue. Unlike wet AMD, its main problem is not leaking abnormal blood vessels.

Two medications have been approved in the United States to slow geographic atrophy progression:

  • Pegcetacoplan (Syfovre): Targets complement proteins C3 and C3b involved in the immune response associated with retinal damage.
  • Avacincaptad pegol (Izervay): Blocks complement protein C5, another part of the immune system involved in the disease process.

These medications are administered as injections into the eye. They are designed to slow enlargement of the damaged retinal areas rather than improve existing vision.

A July 2026 article from Cleveland Clinic explains that these treatments can slow geographic atrophy progression, with clinical trial results showing approximately a 20% reduction in the rate of lesion growth for certain treatment schedules. This does not mean that patients recover 20% of their lost vision.

Are geographic atrophy injections worth considering?

For suitable patients, treatment may help preserve functioning retinal tissue for longer. However, the expected benefit must be balanced against repeated appointments, treatment costs, and possible complications.

Risks include inflammation, infection, retinal detachment, and an increased chance of developing wet AMD. Rare serious complications may also occur.

These medicines are not appropriate for every person with dry AMD. A retina specialist can assess the location and extent of atrophy, current vision, and likely treatment benefit. Availability and approval may also differ between countries.

Does Laser Treatment Still Help Macular Degeneration?

Laser-based treatments have a smaller role in AMD management today because anti-VEGF injections generally offer better options for controlling wet AMD.

Photodynamic therapy

Photodynamic therapy (PDT) combines a light-sensitive medication called verteporfin with a specially directed laser.

The medication is given through a vein and reaches abnormal blood vessels in the eye. When the doctor activates it using the laser, the treatment helps close those vessels and reduce leakage.

PDT may be considered for selected cases of wet AMD, sometimes alongside anti-VEGF injections. Repeat treatment may be necessary.

Traditional laser photocoagulation

Laser photocoagulation uses focused heat to seal abnormal blood vessels. However, the treatment can damage nearby retinal tissue and produce permanent blind spots.

According to Mayo Clinic, laser photocoagulation is used in relatively few wet AMD cases and is generally unsuitable when abnormal blood vessels lie directly beneath the center of the macula.

For most people with wet AMD, anti-VEGF medication remains the preferred treatment approach.

Can Lifestyle Changes Help Protect Remaining Vision?

Healthy habits cannot replace medical treatment, but they can support eye health and may help lower the risk of AMD progression.

Useful measures include stopping smoking, staying physically active, eating a balanced diet, and managing blood pressure and cholesterol.

Foods such as leafy green vegetables, fruit, and other nutrient-rich plant foods can support general eye health. Fish is also commonly included in dietary guidance for AMD.

However, ordinary food choices are not a substitute for AREDS2 supplements when a specialist recommends the studied formulation. Likewise, dietary changes cannot replace anti-VEGF injections for active wet AMD.

What Helps When Macular Degeneration Has Already Caused Vision Loss?

When central vision has been permanently affected, low-vision rehabilitation can make daily activities easier and help people remain independent.

Rehabilitation does not repair damaged retinal cells. Instead, it teaches patients how to use their remaining vision more effectively.

Low-vision devices and practical support

Depending on individual needs, helpful tools may include magnifiers, electronic reading devices, brighter task lighting, large-print materials, and speech-based technology.

A low-vision specialist or occupational therapist can also suggest adjustments for reading, preparing meals, moving around safely, and managing everyday tasks.

Vision rehabilitation can be valuable alongside medical treatment rather than only after all treatment options have been exhausted.

How Do Eye Specialists Decide Which Treatment Is Best?

The correct treatment depends on more than a person's current eyesight. Ophthalmologists examine the retina to determine the type of AMD, the amount of existing damage, and whether the disease is active.

A comprehensive dilated eye examination and optical coherence tomography (OCT) are commonly used. OCT produces detailed images of the retinal layers and can help identify fluid, tissue thinning, and other changes.

For suspected wet AMD, additional imaging may be used to assess abnormal blood vessels.

Treatment planning generally considers whether the goal is to control leakage, slow disease progression, protect the other eye, or improve the patient's ability to function with reduced vision.

When should changes in vision be assessed urgently?

New distortion of straight lines, a sudden blurry area, or a new dark spot in central vision should be evaluated promptly by an eye care professional. These changes can occur with advanced AMD, including wet AMD, but may also have other causes.

Following an eye injection, significant eye pain, increasing redness, or a sudden decrease in vision needs urgent medical assessment because it may indicate a treatment-related complication.

Are Stem Cell Treatments or Other New Therapies Available?

Researchers are studying ways to replace damaged retinal cells, improve drug delivery, and provide longer-lasting control of AMD.

Stem cell-based retinal treatments remain investigational rather than established routine treatment for macular degeneration. Their long-term benefits and risks still require further evaluation.

Patients interested in emerging treatments can ask a retina specialist about legitimate clinical trials. Experimental interventions should not be treated as proven alternatives to established AMD care.

What Results Can Patients Realistically Expect?

The main goal of macular degeneration treatment is usually to protect vision rather than restore normal eyesight.

For wet AMD, anti-VEGF treatment can often slow or stabilize vision loss, and some people experience improvement. Outcomes are generally better when active disease is identified and treated promptly.

For appropriate patients with intermediate AMD, AREDS2 supplements can reduce the risk of developing advanced disease. In geographic atrophy, newer injections may slow the expansion of damaged retinal areas but do not restore lost vision.

Regular monitoring remains essential because treatment needs can change. Working with an ophthalmologist, especially a retina specialist when advanced AMD is present, helps ensure that treatment decisions reflect current retinal findings and the patient's goals.

Frequently Asked Questions

Answers to common questions about the effectiveness, safety, and long-term use of macular degeneration treatments.

Can macular degeneration be reversed with treatment?

There is currently no cure that completely reverses macular degeneration. Anti-VEGF injections may improve vision in some people with wet AMD by reducing retinal fluid and leakage. However, treatments cannot reliably restore retinal cells that have already been permanently damaged.

What is the most effective treatment for wet macular degeneration?

Anti-VEGF eye injections are the established first-line treatment for most people with wet AMD. Medications such as aflibercept, ranibizumab, and faricimab help control abnormal blood vessel activity. A retina specialist determines which medicine and injection schedule are most suitable.

Do eye injections for macular degeneration hurt?

Eye doctors use numbing medication before giving the injection, so most people experience pressure or brief discomfort rather than significant pain. Temporary irritation may occur afterward. Severe or worsening pain is not expected and requires urgent medical attention.

Are AREDS2 vitamins helpful for every person with macular degeneration?

No. AREDS2 supplements are mainly useful for people with intermediate AMD or advanced AMD in only one eye. They do not treat active wet AMD, reverse existing vision loss, or provide proven benefits for everyone with early AMD. An ophthalmologist can determine whether they are appropriate.

Will macular degeneration injections be needed for life?

Some patients need injections for an extended period, particularly with wet AMD. Others may be able to increase the time between treatments depending on retinal findings and disease activity. Treatment schedules should be adjusted by the eye specialist rather than stopped without medical guidance.

Citations

  1. National Eye Institute — Age-Related Macular Degeneration (AMD)
  2. National Eye Institute — Treatments for Wet AMD (Advanced Neovascular AMD)
  3. National Eye Institute — AREDS 2 Supplements for Age-Related Macular Degeneration
  4. Cleveland Clinic — How Eye Injections Work for Geographic Atrophy
  5. Mayo Clinic — Wet Macular Degeneration: Diagnosis and Treatment
Share this article